ATE142884T1 - Verwendung von magnesium-pyridoxal-5'-phosphat- glutaminat zur verhinderung von krankheiten verursacht durch gefässläsionen - Google Patents

Verwendung von magnesium-pyridoxal-5'-phosphat- glutaminat zur verhinderung von krankheiten verursacht durch gefässläsionen

Info

Publication number
ATE142884T1
ATE142884T1 AT91108217T AT91108217T ATE142884T1 AT E142884 T1 ATE142884 T1 AT E142884T1 AT 91108217 T AT91108217 T AT 91108217T AT 91108217 T AT91108217 T AT 91108217T AT E142884 T1 ATE142884 T1 AT E142884T1
Authority
AT
Austria
Prior art keywords
glutaminate
phosphate
vascular lesions
diseases caused
preventing diseases
Prior art date
Application number
AT91108217T
Other languages
English (en)
Inventor
Werner Dr Rer Nat Schneider
Britta Meyer
Erich F Prof Dr Elstner
Original Assignee
Steigerwald Arzneimittelwerk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Steigerwald Arzneimittelwerk filed Critical Steigerwald Arzneimittelwerk
Application granted granted Critical
Publication of ATE142884T1 publication Critical patent/ATE142884T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91108217T 1990-05-25 1991-05-22 Verwendung von magnesium-pyridoxal-5'-phosphat- glutaminat zur verhinderung von krankheiten verursacht durch gefässläsionen ATE142884T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4016963A DE4016963A1 (de) 1990-05-25 1990-05-25 Verwendung von magnesium-pyridoxal-5'-phosphat-glutaminat zur verhinderung von erkrankungen, die sich infolge von gefaessschaeden ergeben

Publications (1)

Publication Number Publication Date
ATE142884T1 true ATE142884T1 (de) 1996-10-15

Family

ID=6407228

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91108217T ATE142884T1 (de) 1990-05-25 1991-05-22 Verwendung von magnesium-pyridoxal-5'-phosphat- glutaminat zur verhinderung von krankheiten verursacht durch gefässläsionen

Country Status (28)

Country Link
US (1) US5372999A (de)
EP (1) EP0458287B1 (de)
JP (1) JPH07119174B2 (de)
KR (1) KR970005180B1 (de)
CN (1) CN1050750C (de)
AT (1) ATE142884T1 (de)
AU (1) AU651108B2 (de)
CA (1) CA2043228C (de)
CZ (1) CZ280683B6 (de)
DE (2) DE4016963A1 (de)
DK (1) DK0458287T3 (de)
EG (1) EG19730A (de)
ES (1) ES2091262T3 (de)
GR (1) GR3021077T3 (de)
HR (1) HRP931445B1 (de)
HU (1) HU219223B (de)
IE (1) IE76728B1 (de)
IL (1) IL98156A (de)
IN (1) IN173057B (de)
LT (1) LT3335B (de)
LV (1) LV10046B (de)
MD (1) MD306C2 (de)
MX (1) MX171883B (de)
RU (1) RU2041713C1 (de)
SI (1) SI9110925A (de)
SK (1) SK278896B6 (de)
UA (1) UA26973A1 (de)
ZA (1) ZA913692B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19527820A1 (de) * 1995-07-28 1997-01-30 Leniger Follert Elfriede Prof Arzneimittel zur Behandlung von Ulcera, insbesondere bei arteriellen und venösen Durchblutungsstörungen der Extremitäten, bei chronisch venöser Insuffizienz und Lymphödem
DE19532625C2 (de) * 1995-09-04 2000-04-20 Steigerwald Arzneimittelwerk Verfahren zur Herstellung von Magnesium-pyridoxal-5'-phosphat-glutamat und dabei erhaltene Zwischenprodukte
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
EP1169322B8 (de) 1999-03-08 2006-09-13 Medicure Inc. Pyridoxal-analoge zur behandlung von störungen ausgelöst durch einen vitamin b6 mangel
WO2001003682A2 (en) * 1999-07-13 2001-01-18 Medicure Inc. Use of pyridoxin derivatives for the treatment of diabetes and related complications
EP1872797A3 (de) * 1999-08-24 2008-04-02 Medicure International Inc. Behandlung kardiovaskulärer und verwandter Leiden
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
DE60110054T2 (de) 2000-02-29 2006-03-09 Medicure International Inc. Cardioprotektive phosphonate
EP1278526A2 (de) 2000-03-28 2003-01-29 Medicure International Inc. Behandlung von zerebrovaskulären erkrankungen
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
ATE364595T1 (de) 2000-07-07 2007-07-15 Medicure Int Inc Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
US6897228B2 (en) 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
US7812037B2 (en) 2004-10-28 2010-10-12 Medicure International, Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US7459468B2 (en) 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
CA2680801A1 (en) 2007-03-14 2008-09-18 Sierra Molecular Corporation Compositions, systems, and methods for preservation and/or stabilizationof a cell and/or macromolecule
RU2484843C1 (ru) * 2012-04-03 2013-06-20 Алексей Кириллович Пехтерев Лекарственный сбор растений для лечения сердечно-сосудистых заболеваний

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE246172C (de)
DE2461742C2 (de) * 1974-12-28 1983-01-27 Steigerwald Arzneimittelwerk Gmbh, 6100 Darmstadt Pyridoxin-5'-phosphorsäureester-Derivate sowie deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE3807895A1 (de) * 1988-03-10 1989-09-21 Knoll Ag Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker

Also Published As

Publication number Publication date
KR970005180B1 (ko) 1997-04-14
LV10046A (lv) 1994-05-10
HRP931445A2 (en) 1996-02-29
LT3335B (en) 1995-07-25
US5372999A (en) 1994-12-13
KR910019616A (ko) 1991-12-19
HUT58204A (en) 1992-02-28
CZ280683B6 (cs) 1996-04-17
MX171883B (es) 1993-11-22
SI9110925A (sl) 1998-06-30
ZA913692B (en) 1992-02-26
AU651108B2 (en) 1994-07-14
IL98156A (en) 1996-06-18
IL98156A0 (en) 1992-06-21
EP0458287B1 (de) 1996-09-18
AU7730191A (en) 1991-11-28
MD306C2 (ro) 1996-02-29
DE69122170D1 (de) 1996-10-24
CN1050750C (zh) 2000-03-29
GR3021077T3 (en) 1996-12-31
IN173057B (de) 1994-02-05
DE69122170T2 (de) 1997-02-20
EP0458287A2 (de) 1991-11-27
RU2041713C1 (ru) 1995-08-20
SK278896B6 (sk) 1998-04-08
JPH04235130A (ja) 1992-08-24
MD306B1 (ro) 1995-10-31
CS156391A3 (en) 1992-02-19
JPH07119174B2 (ja) 1995-12-20
DE4016963A1 (de) 1991-11-28
UA26973A1 (uk) 2000-02-28
CA2043228C (en) 1998-07-14
HU911756D0 (en) 1991-12-30
HRP931445B1 (en) 2000-04-30
IE76728B1 (en) 1997-11-05
DE4016963C2 (de) 1992-04-30
CN1057391A (zh) 1992-01-01
EP0458287A3 (en) 1992-04-08
LTIP580A (en) 1994-12-27
EG19730A (en) 1996-01-31
HU219223B (en) 2001-03-28
ES2091262T3 (es) 1996-11-01
DK0458287T3 (da) 1996-10-07
CA2043228A1 (en) 1991-11-26
IE911783A1 (en) 1991-12-04
LV10046B (en) 1995-02-20

Similar Documents

Publication Publication Date Title
ATE142884T1 (de) Verwendung von magnesium-pyridoxal-5'-phosphat- glutaminat zur verhinderung von krankheiten verursacht durch gefässläsionen
DE59310327D1 (de) Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
ES2095380T3 (es) Derivados de indano-2-carboxialquilo sustituidos en la posicion 2 utiles como inhibidores de la encefalinasa y la eca.
EP0363415A4 (en) Compounds for the treatment of alzheimer's disease
ATE135208T1 (de) Verwendung von nervonsäure und langkettiger fettsäuren zur behandlung demyelinisierender erkrankungen
DE69600084D1 (de) Verwendung von hydroxylierte Carbonsäure zur Behandlung von Nägeln
ATE83378T1 (de) Verwendung von 3'-azido-deoxythymidin zur herstellung eines arzneimittels zur behandlung von humanen brustcarzinomen.
DE69420776D1 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
LV12251A (lv) 2-fenil-1,2-benzizoseleazol-3(2h)-ona pielietojums medikamenta razosanai kas paredzets alcheimera slimibas profilaksei un/vai terapijai
ATE77560T1 (de) Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen.
ATE227557T1 (de) Verwendung von zahnpflegemitteln enthaltend bovines kolostrum
DE69207885D1 (de) Gammalinolensäure zur Herstellung eines Medikaments zur Verhinderung von Wiederverschluss von Arterien
ATE229336T1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
DE69124415D1 (de) Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen
DE50003730D1 (de) Caspase 8-inhibitoren zur immunsuppression
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
ATE213955T1 (de) Verminderung des fettgewebes durch verwendung von kollagenase
ATE315583T1 (de) Analoge des thymosin alpha 1

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee